Description
Recombinant Human Angiopoietin-related Protein 3/ANGPTL3 (C-Fc) | PKSH033975 | Gentaur US, UK & Europe Disrtribition
Synonyms: Angiopoietin-related protein 3; ANGPTL3; Angiopoietin-5; ANG-5; Angiopoietin-like protein 3; ANGPT5
Active Protein: N/A
Activity: Recombinant Human Angiopoietin-related Protein 3 is produced by our Mammalian expression system and the target gene encoding Ser17-Pro220 is expressed with a Fc tag at the C-terminus.
Protein Construction: Recombinant Human Angiopoietin-related Protein 3 is produced by our Mammalian expression system and the target gene encoding Ser17-Pro220 is expressed with a Fc tag at the C-terminus.
Fusion Tag: C-Fc
Species: Human
Expressed Host: Human Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 95 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per µg as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 50.7 kDa
Formulation: Lyophilized from a 0.2 μm filtered solution of PBS, 5% Trehalose, pH 7.4.
Reconstitution: Please refer to the printed manual for detailed information.
Background: Angiopoietin-like 3 (ANGPTL3) is a secreted glycoprotein that is structurally related to the angiopoietins. Mature human ANGPTL3 contains an N-terminal coiled coil domain and a C-terminal fibrinogen-like domain. ANGPTL3 is expressed in the liver from early in development through adulthood. Full length ANGPTL3 circulates in the plasma as do the proteolytically separated N-and C-terminal segments containing the coiled coil domain and fibrinogen-like domains, respectively. ANGPTL3 directly inhibits lipoprotein lipase (LPL) and endothelial lipase (EL), enzymes responsible for hydrolyzing circulating triglycerides and HDL phospholipids. ANGPTL3 promotes an increase in circulating triglyceride levels without altering VLDL or HDL secretion or uptake. ANGPTL3 expression in vivo is up-regulated by LXR agonists and down-regulated by insulin, leptin, and agonists of TRβ or PPARβ.
Research Area: Signal Transduction, Cardiovascular, Cancer, metabolism,
